? GENE EXPRESSION AND REGULATION The Gene Expression and Regulation Program (GER) is comprised of eight laboratories that work together in the areas of gene transcription and chromatin biology. The overarching goals of the Program match the long- term vision of the Cancer Center to merge basic understanding of fundamental biological mechanisms with translational identification of new, actionable therapeutic targets in cancer. To fulfill this goal, the GER Program brings together complementary and synergistic scientific excellence in three flagship themes: (i) Transcription and Chromatin Organization, (ii) Non-coding RNAs and Epigenetics, and (iii) Chromosomes and Genome Dynamics. In addition, the GER Program is at the forefront of an interdisciplinary theme in Chemical Biology of Novel Cancer Drug Targets, in line with the focus of the Cancer Center in early-stage academic drug discovery. Progress during the last five years has been transformative. GER Program members continued to lead their respective fields of investigation with high-impact publications in the top-tier literature, strengthened their cancer focus and attracted new talents to build ?critical mass? in flagship research themes. The most far-reaching goals set forth in the last Cancer Center Support Grant (CCSG) renewal were also met. GER Program members have now significantly expanded their intra- and inter-programmatic collaborations, increased the utilization of Shared Resources, achieved important basic and translational milestones in the ovarian cancer research continuum signature, and advanced innovative cancer therapeutics to the stage of first-in-human testing. During the last CCSG budget cycle, GER Program members published 104 cancer- related, discovery articles. Of these, 12.5% and 36.5% were the product of intra- or inter-programmatic collaborations, respectively, compared to 7% and 19% of the previous CCSG budget cycle, bringing the total collaborative publications of the Program from 23% in 2013 to more than 43% in 2018. Currently, GER Program members receive $3.4 million in peer-reviewed, cancer-related funding (total funding, $4.9 million), with $2.2 million from the NCI for a strong cancer focus of 64%. In addition, $2.2 million out of $3.4 million (65%) of peer-reviewed funding is the product of internal or external collaborations. Accordingly, the Program is home to two collaborative Program Project grants (P01 CA174439; P01 AG031862) and one multi- institutional Specialized Program of Research Excellence in ovarian cancer (SPORE, P50 CA228991; anticipated funding, 2018). In addition, the Program functions as a regional pole of collaborative research in early-stage drug discovery, leading a Philadelphia Drug Discovery Forum that brings together expertise from academic Institutions and the pharmaceutical and biotechnology industry. The GER Program is ideally poised to continue on this exponential trajectory of research preeminence during the next CCSG budget cycle, integrating basic understanding of biological pathways with impactful collaborations in translational cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-51
Application #
9917713
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
51
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149
Wu, Shuai; Fatkhutdinov, Nail; Fukumoto, Takeshi et al. (2018) SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 9:4116
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Fukumoto, Takeshi; Magno, Elizabeth; Zhang, Rugang (2018) SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Mol Cancer Res 16:1819-1825
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Colón, Krystal; Speicher, David W; Smith, Peter et al. (2018) S100a14 is Increased in Activated Nk Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-Nk crosstalk. J Acquir Immune Defic Syndr :

Showing the most recent 10 out of 741 publications